home / stock / kros / kros news

KROS News and Press, Keros Therapeutics Inc. From 05/08/24

Stock Information
Company Name: Keros Therapeutics Inc.
Stock Symbol: KROS
Market: NASDAQ
Website: kerostx.com
Menu
KROS KROS Quote KROS Short KROS News KROS Articles KROS Message Board
Get KROS Alerts

News, Short Squeeze, Breakout and More Instantly...
KROS - Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorde...
KROS - Keros Therapeutics files automatic mixed shelf

2024-05-03 13:46:32 ET More on Keros Therapeutics Seeking Alpha’s Quant Rating on Keros Therapeutics Historical earnings data for Keros Therapeutics Read the full article on Seeking Alpha For further details see: Keros Therapeutics files automatic ...

KROS - Expected US Company Earnings on Thursday, May 2nd, 2024

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

KROS - Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunc...
KROS - Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunc...

KROS - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disord...

KROS - Veru eyes better weight loss drugs as FDA clears Phase 2 trial

2024-02-06 15:27:22 ET More on Veru Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha For further details see: Veru eyes better weight loss drugs as ...
KROS - Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress

LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that ...

KROS - Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock

LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that ...

KROS - Keros Therapeutics prices upsized stock offering to raise $140 million

2024-01-04 01:04:56 ET More on Keros Therapeutics Keros Therapeutics: Interesting Early Data From A Promising Molecule (Downgrade) Keros falls after mid-stage data for blood cancer therapy Seeking Alpha’s Quant Rating on Keros Therapeutics For further ...
Previous 10 Next 10